Summarized by Masters of Longevity from Longevity Technology.
A preview of an industry update describing a planned FDA meeting to align trial endpoints for a dementia-with-Lewy-bodies psychosis drug, useful for investors and clinicians.
Key Takeaways
- Cognition Therapeutics scheduled a Type C meeting with FDA Division of Neurology for October 20, 2026.
- The meeting will focus on analytical and statistical alignment for the proposed primary endpoint of a Phase 3 registrational trial.
- Cognition reports Phase 2 data where the drug slowed hallucinations and delusions by 89% versus placebo on the neuropsychiatric inventory.
